MedTrace Logo

Effects and Underlying Mechanism of Lipid Lowering Intervention on Vascular Protection in Hypertensive Patients

NCT02254824 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2014-10-02

No results posted yet for this study

Summary

The purpose of EMINENT study is to evaluate the efficacy of Xuezhikang or atorvastatin in hypertensive patients at low/moderate cardiovascular risk.

Conditions

Interventions

DRUG

Xuezhikang

Xuezhikang

DRUG

Atorvastatin

Atorvastatin

BEHAVIORAL

Lifestyle modification

Lifestyle modification

Sponsors & Collaborators

  • Peking University First Hospital

    collaborator OTHER

  • Peking Union Medical College Hospital

    collaborator OTHER

  • Beijing Hospital of Traditional Chinese Medicine

    collaborator OTHER

  • Chinese Academy of Medical Sciences, Fuwai Hospital

    lead OTHER

Principal Investigators

  • Aimin Dang, Doctor · Fuwai Hospital & Cardiovascular Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-10-31
Completion
2016-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02254824 on ClinicalTrials.gov